Psychedelic Business Spotlight: November 12
This week in psychedelic business news: two of the biggest players in the industry unveil big data; Numinus Wellness helps MAPS expand MDMA study; and Ketamine One announces IPO intention.
Psychedelic Spotlight News
Canada Reaches Psychedelic Milestone with First Legal Group Psilocybin Therapy Session
And the results, according to the participants, were nothing short of “profound.”
Jada Pinkett Smith Reveals Psilocybin Helped Her Overcome ‘Crippling Depression’ in ‘Red Table Talk’ About Psychedelics
Will Smith’s wife, and her son, Jaden, lead a “Red Table Talk” about psychedelics with author Michael Pollan and other guests.
MAPS Expands MDMA-Assisted Therapy for PTSD Trial Into Canada
Rick Doblin’s organization partners with Numinus Wellness to manage the Canadian sites where therapists will be administering the psychedelic therapy.
Largest Psilocybin Therapy Trial Ever Conducted Shows Depressive Symptoms Rapidly Reduce
“A single dose of psilocybin generated a rapid response that lasted up to 12 weeks,” explains principal investigator Dr. David J. Hellerstein, who was evaluating Compass Pathways’ novel drug formulation COMP360.
Forgotten Psychedelics: What Is 2C-B?
4-Bromo-2,5-dimethoxyphenethylamine (also known as Nexus, Erox, or 2C-B) was synthesized by a famous American pharmacologist and psychonaut, Alexander Shulgin, in 1974.
Veteran Who Cured PTSD with MDMA-Assisted Therapy Wows NBC ‘Today’ Show Anchors
“This treatment is the reason that my son has a father instead of a folded flag,” a once-suicidal Iraq War veteran tells Savannah Guthrie.
Cybin Unveils Data Suggesting Its Novel Psilocybin Analog Is the ‘Superior Molecule’
Pre-clinical studies demonstrated multiple advantages, including less patient variability, faster onset of action, shorter duration of effect, and improved brain penetration.
Psychedelic Business Spotlight: November 5
This week in psychedelic business news: DEA grants Cybin a Schedule I manufacturing license; PharmaTher partners with Revive Therapeutics on microneedle patch technology; Mydecine patents nanotechnology.
Why We’re Excited About Compass Pathways’ New Clinical Trial Treating PTSD with Psilocybin
Compass Pathways (Nasdaq: CMPS) has announced the launch of a…
End of content
End of content